New Delhi: India must ensure equitable, timely global access to the World Health Organization (WHO) recommended lenacapavir — the first twice-yearly injectable pre-exposure prophylaxis (PrEP) product — to tackle the burden of HIV worldwide, according to an expert on Monday.

Lenacapavir injection as an additional PrEP option offers a highly effective, long-acting alternative to daily oral pills and other shorter-acting options.

With just two doses per year, lenacapavir is a transformative step forward in protecting people at risk of HIV — particularly those who face challenges with daily adherence, stigma, or access to health care.

“India must lead from the front in ensuring equitable and timely global access to lenacapavir,” said Dr. Ishwar Gilada, President Emeritus of the AIDS Society

See Full Page